IMUNON Receives $1.3M from Sale of New Jersey Net Operating Losses
Monday, 25 March 2024, 12:58
IMUNON Secures $1.3M Funding
IMUNON, a clinical-stage drug development company, has generated $1.3 million in funding from the sale of New Jersey net operating losses.
Non-Dilutive Funding Boosts Research Efforts
This strategic financial move provides crucial support for IMUNON's ongoing research and development projects.
- Secured funding through innovative financial strategy
- Utilized New Jersey net operating losses for capital enhancement
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.